𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase I study of an outpatient regimen of recombinant human interleukin-2 and alpha-2a-interferon in patients with solid tumors

✍ Scribed by M. Huberman; H. Bering; B. Fallon; J. Tessitore; H. Sonnenborn; S. Paul; J. Zeffren; D. Levitt; J. Groopman

Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
548 KB
Volume
68
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase I study of recombinant human int
A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma
✍ A. Mittelman; M. Huberman; C. Puccio; B. Fallon; J. Tessitore; S. Savona; R. Eyr πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 662 KB

Preclinical data suggest synergy of interleukin-2 (IL-2) combined with alphainterferon (IFN). In addition, toxicities of IL-2 may be decreased by intermittent continuous infusion. The purpose of this trial was to determine the maximum tolerated dose (MTD) of recombinant IL-2 combined with alpha-IFN

A phase I study of subcutaneous recombin
A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a
✍ Mark J. Ratain; Edwin R. Priest; Linda Janisch; Nicholas J. Vogelzang πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 495 KB πŸ‘ 2 views

Background. Both recombinant in1 erferon alfa and interleukin-2 (IL-2) have been shown to lave some activity as single agents in metastatic renal cj !I1 cancer (RCC), although their activity is minimal in mo -e common solid tumors. Recent preclinical studies hav ? suggested that the combination of t